Drugs / PG13-CEA_TCR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00923806 | Dec 2008 → Nov 2011 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG13-CEA_TCR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923806 ↗ |
| Known as | Anti-CEA TCR PBL | “PG13-CEA_TCR (Anti-CEA TCR PBL)” NCT00923806 ↗ |
| Action | Deplete | “The modified cells (anti-CEA cells) are grown in the laboratory and then given back to the patient to try to decrease the size of the tumors.” NCT00923806 ↗ |
| Modality | Cell therapy | “Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes” NCT00923806 ↗ |
| Route | Intravenous | “The cells are given as an infusion through a vein.” NCT00923806 ↗ |